Navigation Links
New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
Date:6/30/2008

SILVER SPRING, Md., June 30 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary, Lung Rx, Inc., announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of an inhaled formulation of treprostinil (ITRE) for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disease. The submission starts a 60-day period during which the FDA will examine the application for completeness. If the FDA accepts the ITRE NDA for review, then it is expected to be subject to the standard 10- to 12-month review period before an action letter is issued.

"We believe that an inhaled formulation of treprostinil will be a very desirable option for PAH patients," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "The completion of the NDA filing is a huge milestone in United Therapeutics' quest to develop as many formulations of treprostinil as possible to create better, more convenient therapies to treat the debilitating effects of PAH along the full spectrum of the disease."

The ITRE NDA is principally supported by data from the TRIUMPH-1 Phase III clinical trial.

About TRIUMPH-1

TRIUMPH-1 (TReprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension), was a randomized, double-blind, placebo- controlled trial of patients with PAH. ITRE is prepared once per day and administered in four daily inhalation sessions using the NEBU-TEC Optineb(TM) ultrasonic nebulizer, with each inhalation session taking approximately 1-2 minutes.

The TRIUMPH-1 clinical trial is one of the first pivotal trials to assess the increment
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)
2. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
3. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications
4. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
5. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
6. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
7. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
8. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
9. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
10. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
11. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... a third of reproductive-aged women enrolled in Medicaid, and more ... prescription for an opioid pain medication each year during 2008-2012, ... Weekly Report (MMWR). Opioids are typically prescribed ... They are also found in some prescription cough medications. The ...
(Date:1/23/2015)... Jan. 23, 2015  HyGreen, Inc., a leader in hand ... with RCA Medical, a subsidiary of Ascendis Health Limited, ... Each year, hundreds of millions of patients around ... organisms are transmitted from patient to patient via the ...
(Date:1/23/2015)... LAS VEGAS , Jan. 23, 2015 Cord Blood ... CBAI ) ("CBAI" or the "Company")  filed a Preliminary Proxy ... ( www.sec.gov ) today, and provides an update for shareholders ... authorized shares is requested. Dear Shareholders, ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... , GENEVA, Switzerland, December 14 ... Meeting was held,in Bermuda on 7th December. In excess of ... and overwhelmingly approved all the resolutions,put forward. , ... Shortt of Galmoy,as the new Director of Corporate Communications. In ...
... , , STUART, ... LBMH) is pleased to announce the addition of Mr. Joseph Farish ... Farish is s graduate of the University of Florida (Bachelor of ... has been a member of the Florida Bar for more than ...
Cached Medicine Technology:Calcitech Holds Annual General Meeting 2Liberator Medical Strengthens its Board of Directors with the Addition of Mr. Joseph Farish and Mr. Robert S. Cuillo 2Liberator Medical Strengthens its Board of Directors with the Addition of Mr. Joseph Farish and Mr. Robert S. Cuillo 3Liberator Medical Strengthens its Board of Directors with the Addition of Mr. Joseph Farish and Mr. Robert S. Cuillo 4
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) ... to “Live Fearless.” , The “Faces of Fearless” ... about how they or someone they know has faced a ... the moment. By telling these types of stories through livefearlessmn.com, ...
(Date:1/22/2015)... January 22, 2015 The federal court overseeing ... U.S. District Court, Southern District of West Virginia has upheld ... that proceeding’s first bellwether trial. In an Order dated January ... trial after finding that C.R. Bard had not proven a ...
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... The University HealthSystem Consortium (UHC) introduced the Tactics ... center to help its academic medical center members ... challenges of the current economic conditions have increased ... cost reduction initiatives and ideas. UHC,s Tactics ...
... had deficient levels, study shows , , WEDNESDAY, April 29 (HealthDay ... ill patients, new research shows. , In a small study, ... intensive care unit were deficient in vitamin D. , "Vitamin ... patients," said study author Dr. Paul Lee, an endocrinologist and ...
... ongoing debate regarding Hormone Replacement Therapy has been raging ... results of a controversial study released in 2002 have ... how to deal with unpleasant menopausal hormone symptoms caused ... and figures such as Oprah Winfrey, Suzanne Somers and ...
... GuidanceST. LOUIS, April 29 Express Scripts, Inc. (Nasdaq: ... operations of $214.7 million, or $0.86 per diluted share, which ... 2008. The Company reported first quarter cash flow from continuing ... year. "It has been a strong start to 2009 ...
... April 29 A drug widely used to treat ... legs syndrome (RLS) and helps people with the disorder get a ... as part of the Late-breaking Science Program at the American Academy ... 2, 2009. RLS affects up to one in ten people.The ...
... dangerous levels of artery-blocking proteins , , WEDNESDAY, April 29 ... artery disease has worked well in a small trial, ... of the protein collagen, which plays a major role ... von zur Muehlen, a fellow in cardiology at University ...
Cached Medicine News:Health News:University HealthSystem Consortium Launches Tactics for Tough Times Initiative to Help Members With Issues Such as Capacity and Medication Management 2Health News:Critically Ill Patients Lack Vitamin D 2Health News:Critically Ill Patients Lack Vitamin D 3Health News:Women's International Pharmacy Offers Free Educational Information About Bioidentical Hormone Replacement Therapy 2Health News:Women's International Pharmacy Offers Free Educational Information About Bioidentical Hormone Replacement Therapy 3Health News:Express Scripts Reports First Quarter EPS of $0.86, up 23% 2Health News:Express Scripts Reports First Quarter EPS of $0.86, up 23% 3Health News:Express Scripts Reports First Quarter EPS of $0.86, up 23% 4Health News:Express Scripts Reports First Quarter EPS of $0.86, up 23% 5Health News:Express Scripts Reports First Quarter EPS of $0.86, up 23% 6Health News:Express Scripts Reports First Quarter EPS of $0.86, up 23% 7Health News:Express Scripts Reports First Quarter EPS of $0.86, up 23% 8Health News:Express Scripts Reports First Quarter EPS of $0.86, up 23% 9Health News:Express Scripts Reports First Quarter EPS of $0.86, up 23% 10Health News:Express Scripts Reports First Quarter EPS of $0.86, up 23% 11Health News:New Treatment Discovered for Restless Legs Syndrome Improves Sleep 2Health News:Urine Test for Heart Disease Shows Promise 2
... Available in even sizes 20-36F. A ... patient comfort., ,The Latex-Free Robertazzi ... patient comfort while offering the best ... economically priced allowing you to offer ...
Silkolatex™ . Adjustable flange. Single use....
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
Guedel-style enclosed center channel. Semirigid, nontoxic polyethylene with color-coded bite block. Individually packaged, 48 per case. Latex Free....
Medicine Products: